Maprotiline treatment in depression. A perspective on seizures

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Psychiatry

Background:

• Maprotiline hydrochloride is a tetracyclic antidepressant used for treating depression.
• Seizures are a known, albeit rare, adverse effect associated with maprotiline hydrochloride treatment.
• Previous studies and manufacturer data have indicated a link between maprotiline dosage and seizure occurrence.

Purpose of the Study:

• To analyze seizure events in patients treated with maprotiline hydrochloride.
• To identify risk factors associated with maprotiline-induced seizures.
• To propose strategies for mitigating seizure risk in patients receiving maprotiline.

Main Methods:

• Retrospective review of 11 cases of maprotiline hydrochloride-induced seizures at McLean Hospital.
• Analysis of 87 seizure cases reported to the manufacturer (Ciba-Geigy).
• Comparison of dosage regimens, duration of treatment, and plasma drug levels in patients experiencing seizures.

Main Results:

• Most seizures occurred at high maprotiline dosages, sometimes after prolonged stable dosing.
• Neither rapid dose escalation nor high plasma levels were consistently linked to seizure occurrence.
• A significant proportion of seizures (10/11 at McLean Hospital, 60% reported to manufacturer) occurred at dosages exceeding revised guidelines.

Conclusions:

• A long-acting metabolite of maprotiline may contribute to seizure risk.
• Adherence to revised dosage guidelines, particularly reducing maximum dosage after six weeks, could further decrease seizure incidence.
• Adjusting maprotiline prescribing regimens may enhance patient safety by lowering the risk of seizures.